EpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts.
The firm also said it has reached agreement with US firm Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis using its Genedrive molecular point-of-care platform.
The TB supply and distribution agreement includes an upfront payment of $1.0m with further milestone payments of up to $3.0m, alongside escalating supply volumes over the next five years.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The Genedrive diagnostic device, described last October by EpiStem's Chief Executive Officer Matthew Walls in an interview with Sharecast as a gizmo "bigger than an iPod but smaller than an iPad", provides a quick, low cost, and simple-to-use device, which could prove a real boon to medical practitioners in parts of the world where a trip to the local doctor is not really a viable option.
The Genedrive platform and TB test have recently received registration, and regulatory submissions are now in preparation for the Indian market.
The share price fell 0.61% yo 407.50p by 09:27.
NR
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
